Intec Pharma Ltd.
If you purchased Intec Pharma Ltd. securities and would like to join the action, please click "Join This Action" below.
INTEC PHARMA MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE MERGER OF INTEC PHARMA LTD. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – NTEC
March 16, 2021.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Intec Pharma Ltd. (NASDAQ: NTEC) and Decoy Biosystems, Inc. is fair to Intec shareholders.
Upon completion of the merger, former Decoy stockholders are expected to own approximately 75% of the combined company, and Intec shareholders are expected to own approximately 25% of the combined company, calculated on a fully diluted basis.
The investigation concerns whether Intec and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Intec shareholders; and (2) disclose all material information necessary for Intec shareholders to adequately assess and value the merger consideration.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.